{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=43", "query": { "condition": "Dermatologic Disorders", "page": 43 }, "page_size": 10 }, "pagination": { "page": 43, "page_size": 10, "total_count": 13615, "total_pages": 1362, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=44&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=42&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T10:45:45.082Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06626516", "title": "Tebentafusp-tebn With LDT in Metastatic UM", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Uveal Melanoma" ], "interventions": [ { "name": "Tebentafusp-Tebn", "type": "DRUG" }, { "name": "GM-CSF (Sargramostim)", "type": "DRUG" }, { "name": "BCNU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 109, "start_date": "2025-10-15", "completion_date": "2032-08", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-31T10:45:45.082Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06626516" }, { "nct_id": "NCT02932306", "title": "Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Participants With Acne Vulgaris", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acne" ], "interventions": [ { "name": "IDP-121 Lotion", "type": "DRUG" }, { "name": "IDP-121 Vehicle Lotion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "9 Years", "maximum_age": null, "sex": "ALL", "summary": "9 Years and older" }, "enrollment_count": 820, "start_date": "2015-11-03", "completion_date": "2017-02-22", "has_results": true, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-31T10:45:45.082Z", "location_count": 39, "location_summary": "Guntersville, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 34 more", "locations": [ { "city": "Guntersville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Manhattan Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02932306" }, { "nct_id": "NCT04741204", "title": "Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Breast Cancer Stage", "Insulin Resistance", "Racial Bias" ], "interventions": [ { "name": "Metformin Extended Release Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Woman's", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 0, "start_date": "2022-09", "completion_date": "2022-09", "has_results": false, "last_update_posted_date": "2023-07-06", "last_synced_at": "2026-10-31T10:45:45.082Z", "location_count": 1, "location_summary": "Baton Rouge, Louisiana", "locations": [ { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04741204" }, { "nct_id": "NCT00001384", "title": "A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Neoplasms" ], "interventions": [ { "name": "Adriamycin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 35, "start_date": "1994-05", "completion_date": "2001-02", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-10-31T10:45:45.082Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001384" }, { "nct_id": "NCT02597933", "title": "A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Scleroderma, Systemic" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 580, "start_date": "2015-11-12", "completion_date": "2018-11-28", "has_results": true, "last_update_posted_date": "2019-12-13", "last_synced_at": "2026-10-31T10:45:45.082Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02597933" }, { "nct_id": "NCT02124148", "title": "A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Metastasis", "Colorectal Neoplasms", "Breast Cancer" ], "interventions": [ { "name": "Prexasertib", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "LY3023414", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2014-06-18", "completion_date": "2020-02-13", "has_results": false, "last_update_posted_date": "2020-04-01", "last_synced_at": "2026-10-31T10:45:45.082Z", "location_count": 5, "location_summary": "Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02124148" }, { "nct_id": "NCT02220985", "title": "Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Acute Biphenotypic Leukemia", "Acute Leukemia of Ambiguous Lineage", "Acute Undifferentiated Leukemia", "Allogeneic Hematopoietic Stem Cell Transplant Recipient", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Blastic Plasmacytoid Dendritic Cell Neoplasm", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Donor", "Lymphoblastic Lymphoma", "Myelodysplastic Syndrome With Excess Blasts", "Myelodysplastic Syndrome With Excess Blasts-1", "Myelodysplastic Syndrome With Excess Blasts-2", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia in Remission", "Acute Myeloid Leukemia in Remission" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "60 Years", "sex": "ALL", "summary": "Up to 60 Years" }, "enrollment_count": 84, "start_date": "2015-03-23", "completion_date": "2025-05-01", "has_results": true, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-31T10:45:45.082Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania • Seattle, Washington", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02220985" }, { "nct_id": "NCT04967976", "title": "Breast Mesh Used in Two-staged Breast Reconstruction", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Radiation", "Breast Reconstruction", "Synthetic Mesh" ], "interventions": [ { "name": "TiLoop Bra mesh in expander-implant breast reconstrution", "type": "PROCEDURE" }, { "name": "sub-pectoral expander-implant breast reconstruction", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Tianjin Medical University Cancer Institute and Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "18 Years to 70 Years · Female only" }, "enrollment_count": 300, "start_date": "2021-08-01", "completion_date": "2026-08-01", "has_results": false, "last_update_posted_date": "2021-07-20", "last_synced_at": "2026-10-31T10:45:45.082Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04967976" }, { "nct_id": "NCT00735293", "title": "VASER Treatment of Axillary Hyperhidrosis/Bromidrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Axillary Hyperhidrosis" ], "interventions": [ { "name": "VASER", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Commons Aesthetic Plastic Surgery", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2007-04", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2008-09-19", "last_synced_at": "2026-10-31T10:45:45.082Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00735293" }, { "nct_id": "NCT00584935", "title": "Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ocular Cicatricial Pemphigoid" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 3, "start_date": "2006-01", "completion_date": "2026-01-01", "has_results": true, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-31T10:45:45.082Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00584935" } ] }